Control Arm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Long beachUnited statesUnited kingdomJula inrigExchange commissionNational kidney foundationEuropean renal associationTravere therapeutics incEuropean renal association congressSpring clinical meetingsAdjusted indirect comparisonsUnited kingdom radar iga nephropathy populationControl armNefigard posterShows clinically meaningful treatment effectsPatients with iga nephropathy

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesEmanuele pucaAlfredo covelliDario neriSoft tissue sarcomaIndependent dataSafety monitoring boardExperimental armControl armProgression free survivalHazard ratioPress releaseChief medical officerScience translational medicine

Imfinzi and Lynparza Cut Advanced Endometrial Cancer Risk by 45%

Imfinzi and Lynparza Cut Advanced Endometrial Cancer Risk by 45%
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesShannonn westinLynparza imfinziSusan galbraithEuropean society for medical oncologyUniversity of texas md anderson cancer centerMedical oncologyLynparza armImfinzi armControl armImfinzi armsGynecologic oncologyReproductive medicineCancer centerExecutive vice presidentSouth america

AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer

AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomImfinzimonotherapy imfinziarmIndiens wirtschaftSusan galbraithChelsea fordShannonn westinIhre chancenBrendan mcevoyEuropean society for medical oncologyCanadian agency for drugsMerck co incWorld cancer research fund internationalTechnologies in healthUniversity of texas md anderson cancer centerUs electronic health records

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs chemotherapy in advanced or recurrent endometrial cancer

WILMINGTON, Del. (BUSINESS WIRE) Oct 21, 2023

United statesUnited kingdomChelsea fordBrendan mcevoySusan galbraithShannonn westinEuropean society for medical oncologyMerck co incCanadian agency for drugsTechnologies in healthUniversity of texas md anderson cancer centerWorld cancer research fund internationalUs electronic health recordsAmerican cancer societyMedical oncologyControl arm